RC RCKT Rocket Pharmaceuticals, Inc. Loading... : Investor Sentiment and Bull/Bear Views

Premarket movers include Meta rising on a Citi upside catalyst watch, Alvotech jumping on a Barclays double upgrade, Intel gaining on reported SK Hynix talks, JB Hunt sliding on an earnings warning, and Rocket Pharmaceuticals and SimilarWeb rising on Needham upgrades.

The author argues Rocket Pharmaceuticals' Danon program has materially improved after the revised Phase 2 protocol, with the first three patients completing safety observation without TMA, capillary leak syndrome or other major safety concerns. They see the regulatory path as constructive because FDA has not indicated a fundamental pivotal redesign and has encouraged development in female Danon patients, while KRESLADI approval and the $180M Priority Review Voucher sale extend cash runway into Q2 2028. The stated catalyst is the next regulatory and clinical updates expected in H2 2026, with RP-A501 viewed as increasingly interesting as the story develops. The main stated risk is that the program is not fully de-risked and more patients are still needed to confirm the safety improvement.

The author argues Rocket Pharmaceuticals (RCKT) approval odds for its March 28 PDUFA are better than the market price implies because it targets an ultra-rare pediatric disease with no approved curative options, where the FDA applies flexibility and single-arm data is acceptable. The clinical package shows durable efficacy and a safety profile consistent with other approved AAV gene therapies, while orphan and RMAT designations support approval. He states this is high-risk biotech and a binary event, but the downside is known and the upside is asymmetric, so he started a long position into the PDUFA.